Lurbinectedin
Lurbinectedin is a pharmaceutical drug with 38 clinical trials. Currently 20 active trials ongoing. Historical success rate of 71.4%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
18
Early Stage
11
Mid Stage
7
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
50.0%
5 of 10 finished
50.0%
5 ended early
20
trials recruiting
38
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Lurbinectedin + Doxorubicin In Leiomyosarcoma
Lurbinectedin in FET-Fused Tumors
Clinical Trials (38)
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Lurbinectedin + Doxorubicin In Leiomyosarcoma
Lurbinectedin in FET-Fused Tumors
Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer
Study of Trilaciclib and Lurbinectidin
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
Clinical Study in Patients With DSRCT
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 38